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O O R S P R O N K E L IJ K E  A R T I K E L E N
Relative bioavailability o f chloral hydrate after rectal administration o f different 
dosage forms
DRS. D. D. BREIMER1, DRS. H. L. M. COX2 AND PROF. DR. J. M. VAN ROSSUM1
SUMMARY
Relative bioavailability o f chloral hydrate (c h ) after 
rectal administration of different dosage forms was 
investigated.
Several types of rectioles and suppositories, containing 
1000 mg ch  each, were prepared and tested technically. 
For the in vivo studies the following material was chosen:
rectiole with c h  dissolved in sesame oil, a rectiole with 
c h  dissolved in p e g  300, a suppository with c h  in Estarine 
D  base and a suppository with c h  in a base of peg  
1540/6000 (4 : 1). Preparation procedures are described in 
detail. The in vitro disintegration times were determined 
for the suppositories.
The dosage forms were administered to healthy, male 
volunteers. Blood concentrations of trichloroethanol 
(tce ), the active metabolite of c h , were determined at 
fixed time intervals by gas chromatography with electron 
capture detection employing head space analysis. Relative 
bioavailability was calculated by taking the area under the 
blood concentration-time curve from t =  o to t =  00 
(a u c) and comparing it to the a u c  obtained with the p eg  
suppository (100%). The mean value found for the sup­
pository with Estarine D  was 61%, for the p e g  rectiole 
84% and for the rectiole with sesame oil 60%. Conse- 
quently the lipophilic bases are found less effective c h  
delivery systems in comparison to the p e g  bases. Absorp- 
tion rates from the suppository bases were quitefastand 
peak levels were attained after 1l2-2 hours.
•  The conclusion reached was that in general practice the e g  suppository is the preferable dosage form for rectal administration of chloral hydrate.
SAM EN VATTIN G
De relatieve biologische beschikbaarheid van chloral- 
hy draat (c h ) na rectale toediening van verschillende doseer- 
vormen werd onderzocht. Verscheidene soorten rectiolen 
en zetpillen a 1000 mg c h  werden bereid en aan een 
serie proefnemingen onderworpen. Voor de in-vivo-proe­
ven werden de volgende preparaten gekozen: een rectiole 
met c h  opgelost in sesamolie, een rectiole met c h  opge­
lost in polyethyleenglycol (p e g ) 300, een zetpil met c h  
in Estarine D  en een zetpil met c h  in p e g  i  540/6000 (4 : 1). 
Bijzonderheden over de bereidingswijze worden in dit 
artikel beschreven. Van de zetpillen werd de uiteenval tijd 
in vitro bepaald.
De doseervormen werden toegediend aan gezonde vrij­
willigers van het mannelijk geslacht. De concentraties in 
het bloed van trichloorethanol (t c e ), de werkzame meta-
boliet, werden na vastgestelde tijdintervallen bepaald door 
middel van een specifieke gaschromatografische methode.
De relatieve biologische beschikbaarheid werd bere­
kend door het oppervlak onder de plasm aconcentratie- 
tijd-curve (a u c) van t =  o tot t =  00 te nemen en te ver­
gelijken met de a u c , verkregen m et de PEG-zetpil (100%). 
De gemiddelde waarde was voor de Estarine-D-zetpil 61%, 
voor de PEG-rectiole 84% en voor de rectiole m et sesam­
olie 60%. Hieruit volgt dat de lipofiele bases minrW 
effectief werden bevonden m et betrekking tot CH-afgifte 
dan de (hydrofiele) PEG-bases. De resorptiesnelheid uit de  
zetpillen was vrij groot; de piekhoogten werden na 1l t -2  
uur verkregen.
Geconcludeerd wordt dat in de algemene praktijk de 
PEG-zetpillen de voorkeur verdienen wanneer chloral- 
hydraat rectaal moet worden toegediend.
IN T R O D U C T IO N
Chloral hydrate has been used for more than a 
century in hypnotic and sedative drug therapy. 
It is considered as a relatively effective and safe 
sleep-inducing agent (s h a r p l e s s  1970). After 
oral administration of the drug in water solution, 
rapid absorption from the gastrointestinal tract 
takes place (m a r s h a l l  and o w e n s  1954). How- 
ever, the compound is irritating to the gastric 
mucosa and sometimes causes nausea and vomi- 
ting (m a r t in d a l e  1972). Therefore it is generally 
recommended to administer the drug orally, 
well diluted with water or milk. Another possi- 
bility to avoid this unwanted side effect is to 
give the drug rectally in solution (enema) or in a 
suppository. This route is also advantageous 
in children and infants as it avoids the irritation 
and bad taste of oral preparations. Infantile 
convulsions are being treated effectively in this 
way (l o r e n t z  d e  h a a s  and n o a c h  1968).
Despite the widespread use of rectal appli- 
cation of chloral hydrate no data on the effec- 
tiveness of rectal absorption or on the bioavail­
ability have appeared so far. The purpose of 
this investigatïon was to study the absorption
1 Department of Pharmacology, University of Nijmegen, Nijmegen, The Netherlands.
3 Dutch Pharmacists’ Laboratory, 11 Alexanderstraat, The Hague, The Netherlands.
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of chloral hydrate by the rectal route. Four 
different pharmaceutical formulations, two types 
of suppositories and two types of enemas were 
chosen to measure the relative bioavailability 
and absorption rate and to establish the influence 
of vehicle composition. As chloral hydrate (c h ) 
is very rapidly reduced to trichloroethanol (t c e ) 
in the body (b u t l e r  1948; m a r s h a l l  and o w e n s  
1954), so that no unchanged c h  can be measured 
(b r e im e r  et al. 1973), the t c e  blood concentration 
is determined. The absorption of c h  is slower 
than the conversion of chloral hydrate into t c e  
and therefore the initial rise of t c e  blood con­
centration reflects very well the absorption rate 
of chloral hydrate. Bioavailability calculation is 
also based on t c e  blood concentrations.
C H O IC E  OF D O SA G E  FORMS 
A  review of various dosage forms for rectal 
administration of chloral hydrate (c h ) has been 
previously published in this journal (cox 1971). 
These dosage forms have been compared on the 
basis of the requirements as far as data were 
available at that time.
For the present study c h  enemas (rectioles) 
were prepared containing 1000 mg c h  per 3 ml 
dissolved in sesame oil or dissolved in poly- 
ethylene glycol (p e g ) 300. The method of prep- 
aration was that described by cox (1971).
Secondly, suppositories containing 1000 mg 
c h  were prepared for the present study. For c h  
suppositories a fatty base (g s t ir n e r  1960) or a 
p e g  base (Union Carbide Chemicals Comp. 1962) 
are generaliy used. As c h  is more or less soluble 
in the base, resulting in a decrease of the melting 
point, the preparation of suppositories con­
taining 1000 mg c h  often gives rise to difficulties, 
especially if this amount is to be incorporated 
into a fatty base. In addition, the possibility of 
crystallization of c h  has to be taken into ac­
count.
For the preparation of suppositories with c h  
in a fatty base, different types of bases were 
used, separate or in combination, each containing 
a mixture of mono-, di- and triglycerides of 
saturated fatty acids, but with different melting 
ranges (Estarine BC, Estarine C, Estarine D; 
melting range resp. 33-5"35-5°C, 36-38°^, 
40-42°C). An attempt was made to find an 
easily reproducible method of preparation for
this type of suppositories, with c h  either sus- 
pended or dissolved in the base. For suspension- 
suppositories sufficiently fine particles were ob- 
tained by grinding the crystals down, after mixing 
with 0.5% colloidal silica (Aerosil 200), and pass­
ing the mixture through a sieve with 150 mesh 
length. The powder was mixed with the melted 
base (temperature just above the melting point 
in order to prevent substantial dissolution of c h  
in the base) and then the mass was poured into 
moulds. After the preparation of solution-sup- 
positories the mass was examined through a 
microscope for c h  crystallization. Also the 
weight-ratio between c h  and base was varied bji 
using 2.25 and 2.85 ml moulds.
With suspension-suppositories of 2.85 ml an 
attempt was made to stabilize the suspension by 
adding up to 2% colloidal silica. It turned out, 
however, that suppositories of passable hardness 
were obtained only by dissolving c h  in Estarine D 
up to 2.85 ml. At room temperature it takes 
about 2 hours to reach this hardness. Crystal­
lization of c h  in this base could not be excluded 
with certainty.
For the preparation of suppositories with c h  
in a PEG base, the following bases, separate or in 
combination, were tested: p e g  1540, p e g  4000, 
p e g  6000 and hexane-i,2,6-triol. c h  dissolved 
rapidly and completely in the melted bases. 
An easily reproducible method was sought for 
the preparation of suppositories with c h  dissolved 
in a suitable base which were sufficiently har;| 
and nevertheless had a short disintegration time 
in water at 37°C. The congealed mass was also 
examined for c h  crystals. The weight-ratio 
between c h  and base was varied by using 2.25 ml 
and 2.85 ml moulds. It turned out that sup­
positories with satisfactory hardness and with 
the shortest disintegration time in vitro, were 
obtained by using a combination of 4 parts 
p e g  1540 and 1 part p e g  6000 and 2.85 ml 
moulds. At room temperature it took about 
2 hours to achieve this hardness. Crystallization 
of c h  could not be definitely excluded with 
certainty.
Both types of rectioles and suppositories can 
be kept at room temperature for at least 2 
months. Results of an initial investigation on 
the stability are published elsewhere in this 
journal (cox 1973).
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E X P E R IM E N T A L  
Materials
Chloralhydrate (c h ) and Sesame Oil (so) used in this 
study were of Dutch Pharmacopoeia vi grade. 
Polyethylene Glycol 300 (Jefferson, Houston, u s a ). 
Polyethylene Glycol 6000; Carbowax 6000 (Union Car­
bide Chemicals Company, Division of Union Carbide 
Corporation, New York, N .Y. 17, u s a ).
Polyethylene Glycol 1540 (Hoechst, Germany). 
Estarine D  (Edelfettwerke Werner Schlüter, Hamburg- 
Eidelstedt, Germany). Specification supplied by the 
manufacturers: melting range 40-42°C, congealing range 
38-40°C, specific gravity at 2o°C: 0.955-0.975, iodine 
number less than 3, saponification value 220-230, hy- 
droxyl value 30-40.
^^Preparation o f dosage forms
Chloral Hydrate Sesame Oil Rectiole 1000 mg 
(c h -so  rectiole)
Chloral Hydrate 1.10 g
Sesame Oil (2.16 g) to make 3.0 ml
Powder c h  in a wedgewood mortar. Dissolve 
the powder in so in a stoppered glass container 
heating gently. Cool down to room temperature. 
Fill into the rectiole. Screw the canula until it 
fits tightly.
Chloral Hydrate Polyethylene Glycol Rectiole 
1000 m g  (c h -p e g  rectiole)
Chloral Hydrate 1.1 o g
Polyethylene Glycol 300 (2.67 g) to make 3.0 ml
^Preparation as with c h -s o  rectioles.
The rectioles contain 100 mg of c h  in excess, 
as it was estimated that this is about the amount 
which is left behind after administration.
Protect rectioles from light.
Chloral Hydrate Estarine D Suppository 1000 mg 
(CH-Est. D suppository)
Chloral Hydrate i.oog  
Estarine D 2.20 g
Powder c h  in a wedgewood mortar. Dissolve 
the powder in Estarine D heated to 50-70°C in 
a stoppered glass container. Cool down to about 
35°C and pour the mass into a 2.85-ml plastic 
mould.
Chloral Hydrate Polyethylene Glycol Supposi­
tory 1000 m g  (c h -p e g  suppository)
Chloral Hydrate 1.00 g
Polyethylene Glycol 1540 2.08 g 
Polyethylene Glycol 6000 0.52 g
Preparation as with CH-Est. D suppositories.
Plastic suppository moulds have to be used 
because metal will be affected by c h .
Protect suppositories from light.
The content of the preparations used for this 
study was determined according to a modified 
method described by s c h o o r l  (1929).
c h - s o  rectioles and c h - p e g  rectioles o f 1.1 g 
contained 100% and 10 1%  respectively; CH-Est. 
D suppositories and c h - p e g  suppositories of 1 g 
contained 96%  and 102 %  respectively.
Determination o f the disintegration time of the 
suppositories
The test has been performed using an Erweka 
Test Apparatus for suppositories being a part 
of the Erweka ‘All Purpose Disintegration 
Tester Type Z  T 2’.
10 ml water of 37°C was put into a polyethylene 
bag (100 x  50 mm) and then the suppository was 
added. The bag was moved up and down with 
the aid of the apparatus in a waterbath of 37°C  
over 22 mm height between two horizontal 
sticks at 3 mm distance. The time elapsing until 
the suppository was completely melted was 
determined or, at a fixed moment, the fraction 
that had not yet liquified was determined by 
weighing.
In vivo studies
Dosage forms were used 2-6 weeks after prep­
aration.
The subjects were male healthy volunteers, 
mainly medical students, ranging in age from 
20-25 years and in weight from 75-83 kg. They 
had not taken any regular medication during 
the 4 weeks preceding initiation of the study. 
The subjects had been fasting overnight prior 
to the experiments and for 3! hours after ad­
ministration of the drug. At 9.00 A.M. the c h  
dosage form was introduced into the rectum 
and blood samples were taken from a forearm 
vein at i, 1, i j ,  2, 3, 5, 7, 9 and 12 hours 
after administration. (Sometimes a sample was 
omitted due to organization problems.) The 
blood was drawn in tubes containing a small
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drop of heparin solution as anticoagulant. There 
was in no instance early removal of the rectum 
contents by defaecation. For those subjects who 
participated twice in the investigation, there was 
at least an interim of 7 days between the two 
consecutive experiments.
Determination o f TCE in blood by head space 
analysis
Immediately after taking the blood and mixing 
with heparin, 1.0 ml of whole blood was in- 
troduced into a 25.0-ml glass vial, containing
1 ml of lead acetate solution. This compound 
prevents the in vitro conversion of unchanged 
CH into t c e . The vial was equipped with a self- 
sealing sihcon rubber cap and put into a water- 
bath (6o°C) until equilibrium was reached 
between vapour and liquid phase. With a gas- 
tight Hamilton syringe a known amount of the 
head space vapour was taken and injected into 
a gas chromatograph with 63Ni-electron capture 
detection [Hewlett & Packard Model 402, 
column 1.80 m, i.d. 3 mm, Gas Chrom Q 
(80-100 mesh), 10% ov-17, I25°C]. The detector 
response was measured by peak height and the 
concentration was calculated by means of cali- 
bration curves. A  typical gas chromatogram of 
t c e  obtained by this procedure is shown in 
Figure 1. Details of the analytical procedure for 
the simultaneous determination of CH, t c e , t c e  
glucuronide and trichloroacetic acid in biological 
samples using head space analysis, will be 
published elsewhere (b r e im e r  et al. 1973). 
Sensitivity obtained for t c e  in blood by this 
procedure is 0.5 mg/liter blood.
r e s u l t s
The individual curves obtained are shown in 
Figure 2 (suppositories) and Figure 3 (rectioles). 
Unfortunately two subjects in the study with 
the rectioles and one with the suppositories were 
not able to participate more than once in the 
study. In Figure 4 the curves per individual, who 
received two different dosage forms, are given.
Absorption rate
There is quite a variation in absorption rates and 
plasma levels between the individuals per dosage 
form. Between lipophilic bases and p e g  bases 
there are great differences in concentration
values. A  rapid initial rise in t c e  concentration 
occurred in all subjects receiving a suppository. 
Absorption is fast and peak concentrations are 
reached between \ and 2 hours after adminis- 
tration. If absorption is regular and takes place 
according to a first order process, as is often the 
case, the half life of absorption (ria) is charac- 
teristic for the absorption rate or rate of avail- 
ability. In Figure 5 an example is given for chloral 
hydrate. The dose, the fia and ?iel determine 
the ?max and Cmax, which can be calculated.
However, a careful analysis o f the concen­
trations in the first few hours reveals that in most 
cases the absorption process cannot be describec^ 
accurately by a first order kinetic process, aniSP 
therefore it seems ill-advised to calculate these 
parameters. Consequently one can obtain only
Fig. 1. Left: head space gas chromatogram with electron 
capture detection of a i-ml blood sample containing 8 (xg 
of thrichloroethanol. Equilibration 3 hours at 6o°C; 
injection volume 1000 (a1 of head space gas. Right: 
equilibration flask (25.0 ml) with rubber cap, containing 
the blood sample
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conc.TCE (rné,/I blood)
Chloralhydrate 1000 m,g rectal 
supp. Est. D
Fig. 2. Individual t c e  blood concentration curves following rectal administration of iooo mg c h  in suppositories to
healthy volunteers
time Chr)
Fig. 3. Individual t c e  blood concentration curves following rectal administration of 1000 mg c h  in rectioles to healthy
volunteers
an overall impression of the time necessary to 
reach the maximum concentration. It seems that 
both suppository bases are able to deliver the 
drug with approximately the same rate to the 
blood stream. With the rectioles there appears 
also to be rapid absorption in two subjects
receiving the peg rectiole, while in the other 
cases absorption is slower and takes place over a 
longer period of time. Althoügh hardly any 
conclusion can be drawn on the basis of only 
two observations, the slow absorption from the 
so rectiole is striking.
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fconcentration TCE  (m ^/l blood)
concentration TCE (mg-/l b lood)
Fig. 4 . Comparison of individual t c e  blood concentration curves following rectal administration of c h  in different
vehicles to the same healthy volunteers
Relative bioavailability
Bioavailability refers to the fraction of the dose 
of a drug administered that reaches the general 
circulation intact. In the case of chloral hydrate 
the amount becoming available is related to 
t c e , as this is the compound measured in vivo. 
The following may be derived:
F  x  D  =  keVJ C d t  =  kü -A U C
in which:
F  =  bioavailability (0 <  F  <  1),
D  =  dose administered,
C  =  blood or plasma concentration. 
ke 1 =  total body clearance constant,
A U C  =  area under the plasma concentration-time curve 
from t =  0 to t =  00.
The kü of t c e  can be determined only after 
intravenous administration and therefore the 
absolute bioavailability cannot be determined 
if only rectal data are available. Moreover, the 
dose in this case is related to chloral hydrate 
and not to t c e , so that the fraction of the dose
that is converted to t c e  also remains uncertain.
However, it is a reasonable assumption that 
in the same individual this fraction is constant 
and also that kA for t c e  remains constant. Theiy 
the relative bioavailability of chloral hydrate* 
from a certain dosage form (1) can be determined 
by comparison to a reference dosage form (11) 
in the same subject.
The following now applies:
Frel
AUC\
AU C,11
If the A UC is not determined to t =  00, then it 
must be corrected to include the undetermined 
AUC. This is quite possible assuming that at 
the last data point, at time t =  t', absorption 
has been completed, using Dost’s law of corre- 
sponding areas (d o s t  1968). The infinite area is 
given by
00 ? 00
ƒ C dt = J  C  ét  +  ƒ C  dt =  A U C  +  O '  ■ r el
subject K.S.---1---- 1---
10 12 
time ( h)
subject W.B.
CHLOBALHYDBATE. 1000 m y, rectal 
rectiole o o PEG fj
9»----- o sesame oil fl
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in which Tel is the overall elimination time con- 
tan. and C" the last blood concentration 
measured for the determination of AUC.
The AUC 's in the experiments of this investi- 
gation were determined by weighing the corre- 
mding areas under the blood concentration- 
curves up to 12 hours after administration. 
>maining area was calculated by multi- 
plying the concentrations at 12 hours by the
overall elimination time constant r d. Because of 
irregularities in absorption it was not possible 
to determine an exact rel (rel =  1.44 x  tt) in each 
subject and it was decided to take one value for 
all individuals: ti =  10 hours - r el =  14.4 hours 
(Fig. 5). Results per individual will hardly be 
influenced by this assumption.
In Table 1 the results are given for the five 
subjects to whom two dosage forms were ad-
Fig. 5 . Blood concentration curve of t c e  on semi-logarithmic scale following rectal administration of 10 0 0  mg c h  in a
*
e g  suppository. From the descending part of the curve the elimination half life can be determined. The dotted line 
represents the absorption rate process. Apparently there is no lag time
t a b l e 1
Subject Age Weight Dosage form Dose Dose/kg A U C  0-12 hr conc. T c  Atia Tötal A UC F
12 hr O-oo
(yr) (kg) (mg) (mg) (mg.hr/1) (mg/1) (mg.hr/1) (mg.hr/1) (°/o)
P .w . 20 75 supp. P E G IOOO 13-3 36.5 2.31 33-3 69.8 100
supp. Est. D 1000 13-3 22.2 1.30 18.7 40.9 59
G .E. 22 82 supp. P E G 1000 12.2 51.8 2.90 41.8 93-6 xoo
supp. Est. D 1000 12.2 20.1 1.18 17.0 37-1 4 0
H .H . 22 75 supp. PE G 1000 13-3 41.0 2.60 37-4 78.4 100
supp. Est. D 1000 13-3 32.5 2 .3 1 33-2 65.7 84
K .S . 2 1 67 reet. p e g 1000 14.9 45-4 3.40 49.0 944 10 0
reet. so 1000 1 4 .9 27.2 1-43 2 0 .6 47.8 5 1
W .B . 25 83 reet. p e g 1000 1 2 .0 33-4 2.40 (9 hr) 34.6 68.0 10 0
reet. so 1000 12.0 19.6 1.61 (9 hr) 23.2 42.8 63
108-1973 Pharmaceutisch Weekblad 1107
time (hr)
Fig. 6. Average t c e  blood concentration curves after rectal administration of the four dosage forms
t a b l e  n  (m ean values)
No. subjects Dosage forms Dose
(mg)
Dose/kg A U C 0-12 hr 
(mg) (mg.hr/l)
conc. 12 hr 
(mg/1)
00
. f C  df 12
(mg.hr/1)
Total A U C
O-00
(mg.hr/1)
F
C/o)
4 supp. PE G 1000 13-7 44-4 2.62 37-7 82.1 100
3 supp. Est. D 1000 12.9 27.1 1.60 23.0 50.1 61 é
4 supp. PE G 1000 14-3 38-6 2.31 3 0 .7 69-3 84 1
2 reet. so 1000 13-5 23-7 1.78 (9 hr) 25.6 49-3 60
ministered. In all cases the p e g  vehicles resulted 
in a higher bioavailability and they were con- 
sidered as the reference dosage form.
These data show clearly a lower bioavail­
ability per individual of the suppositories with 
Estarine D and the rectioles with sesame oil. 
The oily vehicle for the rectal administration of 
chloral hydrate seems to be an inferior delivery 
system compared to the hydrophilic p e g  system.
In Figure 6 the mean plasma concentration 
curves for all four dosage forms are given and 
their bioavailibility is calculated relative to the 
p e g  suppository (Table n). Although the number 
of subjects is limited the conclusion may be drawn
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that the suppositories and rectioles with p e g  
are both quite efficient, whereas the Estarine D 
and sesame oil are both unsatisfactory. These 
data confirm the results in the individual sub­
jects.
Disintegration in vitro
Disintegration of the CH-Est. D suppository 
means melting as the base is not water-miscible. 
Disintegration of the c h -p e g  suppository is a 
combination of melting and dissolving in water. 
When trying to imitate in vitro the disintegration 
in vivo one has to use a limited amount of water, 
in accordance with the situation in vivo, to get
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comparable results. The method used fulfils this 
requirement (10 ml). The liquified p e g  is not 
completely miscible with the amount of water 
available.
The disintegration time for CH-Est. D sup­
positories was 6 minutes. This value had not 
changed significantly after storage for two 
months at room temperature. 50% of c h -p e g  
suppositories liquified in 10 minutes and 90% 
in 30 minutes. After storage for 6 months at 
room temperature these values were unchanged.
ISC U S SIO N  A N D  C O N C L U S IO N
he design and purpose of the study were for 
practical reasons very simple: comparison of 
the same dosage form, but with two different 
vehicles, in the same subject after rectal ad­
ministration. This allows relative bioavailability 
measurement per individual under the assump- 
tions mentioned. Unfortunately some of the 
volunteers were not able to participate in the 
study for a second time, so that only part of the 
design of the experiments could be realized. 
Nevertheless the results are sufficiently important 
to be reported, although the conclusions drawn 
must be considered against the background of a 
limited number of observations.
Some individual curves are given in Figure 4. 
Representation of the results in this way im- 
mediately gives an impression of the differences 
tbetween dosage forms.'
® It is also important to give all the individual 
curves as this gives insight into the variability 
between different individuals. The differences 
are quite great as can be seen from Figure 2 and 
Figure 3. Often in the literature only the mean 
data are reported and these are then treated 
mathematically. The results of such a manipu- 
lation are given in Figure 6 and it may be noted 
that smoother curves are obtained in this way. 
Irregularities in absorption are not reflected 
in these mean curves, whereas they are obvious 
from the individual ones. Information is there- 
fore lost by giving only mean values.
The results indicate a poor bioavailability of 
chloral hydrate from the lipophilic vehicles 
sesame oil and Estarine D, compared to the 
hydrophilic p e g . The fraction absorbed from 
p e g  bases is about the same as obtained after
oral administration of c h  in a mixture (b r e im e r  
et al. 1973).
The reason for these differences is not clear: 
in the rectioles and probably also in the sup­
positories chloral hydrate is dissolved in the 
vehicle; consequently the differences cannot be 
due to partiele size. Chemical incompatibilities 
with chloral hydrate are reported for many 
substances including sesame oil, Carbowax (a 
p e g  brand) (f a ir b r o t h e r  1973) and the sup­
pository bases Witepsol and Imhausen (p e t r ic ic  
and j a l s e n j a k  1971) which are chemically 
related to Estarine D. It seems likely that 
‘chemical incompatibility’ influences the extent 
of c h  release from the different bases to varying 
degrees, probably depending on the nature of 
interaction between c h  and the base. The in 
vitro disintegration results of the suppositories do 
not give any further explanation. On the contrary, 
as far as disintegration is concerned the in vitro 
results do suggest a better absorption from the 
lipophilic base.
Another important factor is the rate at which 
the active compound becomes available in the 
general circulation. Careful analysis of the con- 
centrations in the first few hours reveals that in 
most cases the absorption cannot be described 
accurately by a first order kinetic process. 
Figure 5 is given merely as an example. One can 
obtain an overall impression of the time necessary 
to reach the maximum concentration. This seems 
to be shortest for p e g  suppositories and longest 
for so rectioles. The absorption rate of p e g  
suppositories is indeed lower than after oral 
administration in a mixture. However, it is much 
higher than after administration of Chloraldurat 
Red capsules intended as a sleep-inducing dosage 
form (b r e im e r  et al., to be pubüshed).
Central nervous system (c n s ) depressant effects 
after administration of chloral hydrate in these 
dosage forms are difficult to assess objectively 
as the subjects received the drug in the morning, 
just after waking up. In general there was no 
evident feeling of c n s  depression. However, two 
subjects (w.B., Fig. 3 and g .e ., Fig. 2) did report 
subjective feelings of drowsiness at the time of 
t c e  peak concentration (8.5 and 7.5 mg/1 re­
spectively).
Generally there were no complaints about 
irritation of the rectum after administration of
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the dosage forms and as already mentioned in no 
subject was the defaecation reflex initiated. To 
one subject, who was suffering from haemor- 
rhoids, the Estarine D suppository was irritating 
while the p e g  suppository was not.
Of the dosage forms we investigated in this 
study, rectioles and p e g  suppositories are the 
easiest to prepare. From the stability point of 
view, so- rectioles and p e g  suppositories are 
preferable. The quantity administered, using the 
rectioles, is probably less exact.
As appears from the results of this study p e g  
suppositories are the best as far as absorption 
rate and bioavailability are concemed. If, more- 
over, p e g  suppositories cause no irritation of the 
rectum this dosage form is preferable. By using 
this dosage form in children instead of the usual 
so rectioles, perhaps the dose can be reduced.
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